Loading…
Becton, Dickinson and Company is projected to rise to $172.48 by 2027, a +17% move from its current price of $147.24. BDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $145.07 | $147.27 | $149.51 | +0.02% |
| May 30 | $144.19 | $147.30 | $150.48 | +0.04% |
| May 31 | $143.54 | $147.34 | $151.24 | +0.07% |
| Jun 1 | $142.99 | $147.37 | $151.88 | +0.09% |
| Jun 2 | $142.51 | $147.40 | $152.46 | +0.11% |
| Jun 3 | $142.08 | $147.43 | $152.98 | +0.13% |
| Jun 4 | $141.70 | $147.47 | $153.47 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $141.70 | $147.47 | $153.47 | +0.15% |
| Week 2 | $139.59 | $147.69 | $156.27 | +0.31% |
| Week 3 | $138.04 | $147.92 | $158.51 | +0.46% |
| Week 4 | $136.78 | $148.15 | $160.46 | +0.62% |
| Week 5 | $135.70 | $148.37 | $162.23 | +0.77% |
| Week 6 | $134.76 | $148.60 | $163.87 | +0.93% |
| Week 7 | $133.91 | $148.83 | $165.41 | +1.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Becton, Dickinson and Company (BDX) is a healthcare company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. It offers a broad range of medical supplies and diagnostic products, covering IV catheters, central lines, surgical products, and laboratory diagnostics.
BDX is a healthcare stock with a current price of $147.63 and a market capitalization of $40.68B, ranking 359. This positioning places it among mid-sized healthcare names with a diversified product portfolio.
The stock trades near key moving averages, with the 50-day SMA at $152.49 and the 200-day SMA at $154.60, and its RSI sits at 50, indicating neutral momentum. A nearby support level is at $142.35 and resistance at $158.64, framing a near-term trading range.
A major floor 9.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.3% below — buyers have tended to step in here.
The nearest ceiling, 7.7% above — a clean break opens room to run.
A major ceiling 25.9% above — clearing it would confirm fresh momentum.
Key BDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $147.16 | Buy | $147.00 | Buy |
| MA 10 | $145.72 | Buy | $146.70 | Buy |
| MA 20 | $146.47 | Buy | $147.61 | Sell |
| MA 50 | $151.99 | Sell | $151.87 | Sell |
| MA 100 | $159.39 | Sell | $154.64 | Sell |
| MA 200 | $154.58 | Sell | $155.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.16 | Neutral |
| Stoch RSI (14) | 73.11 | Neutral |
| CCI (20) | 25.11 | Neutral |
| Williams %R (14) | -55.18 | Info |
| MACD (12,26,9) | 0.66 | Buy |
| ROC (12) | -1.47 | Sell |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 44.82 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -2.75 | Sell |
| Ultimate (7,14,28) | 62.90 | Neutral |
| Momentum (10) | -0.27 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 148.19 | Sell |
| ADX (14) | 16.27 | Neutral |
| ATR (14) | 1.93 | Info |
Near-term momentum appears neutral with RSI at 50 and price oscillating around key moving averages. The 50-day SMA is $152.49 and the 200-day SMA is $154.60, suggesting a lack of clear trend yet price staying within a typical range.
The 30-day price range spans from a low of $132.81 to a high of $164.10, with a defined support at $142.35 and resistance at $158.64. This provides a framework for possible near-term moves within a relatively wide band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $142.35 | $147.24 | $205.36 | 0% | Neutral | |
| $140.90 | $172.48 | $220.99 | +17% | Neutral | |
| $148.43 | $185.00 | $243.24 | +26% | Bullish | |
| $162.37 | $205.45 | $275.74 | +40% | Bullish | |
| $161.63 | $207.23 | $283.06 | +41% | Bullish | |
| $175.21 | $227.36 | $315.39 | +54% | Bullish | |
| $204.87 | $268.83 | $378.16 | +83% | Bullish | |
| $227.75 | $301.97 | $430.21 | +105% | Bullish | |
| $242.86 | $325.20 | $468.79 | +121% | Bullish | |
| $245.38 | $331.67 | $483.39 | +125% | Bullish | |
| $349.82 | $493.07 | $752.87 | +235% | Bullish | |
| $591.50 | $894.01 | $1,462.84 | +507% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $142.35 | $147.24 | $172.79 | +0.00% |
| June 2026 | $127.85 | $149.14 | $177.35 | +1.29% |
| July 2026 | $128.03 | $150.21 | $180.32 | +0.72% |
| August 2026 | $132.61 | $156.30 | $188.99 | +4.05% |
| September 2026 | $136.40 | $161.35 | $196.26 | +3.24% |
| October 2026 | $135.91 | $161.32 | $197.28 | -0.02% |
| November 2026 | $136.46 | $162.45 | $199.60 | +0.70% |
| December 2026 | $139.37 | $166.40 | $205.36 | +2.43% |
Click any year to see its month-by-month BDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BDX could reach as high as $205.36, with a base case around $147.24 and support toward $142.35 — roughly 0% from $147.24. A consolidation phase looks the most probable path here.
Expect BDX to range from $140.90 to $220.99 through 2027. The $172.48 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
The BDX price prediction for 2028 points to an average of $185.00 (low $148.43, high $243.24) — a potential gain of +26% on today's $147.24. Buyers look set to stay in control over this stretch.
In 2029, BDX is projected to trade between $162.37 and $275.74, averaging $205.45 — a potential gain of +40% from today's $147.24. That is up +11% on the projected 2028 average. Momentum favours further upside here.
Becton, Dickinson and Company's 2030 outlook centres on $207.23, within a $161.63 to $283.06 range. That is up +1% on the projected 2029 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, BDX could reach as high as $315.39, with a base case around $227.36 and support toward $175.21 — roughly +54% from $147.24. Momentum favours further upside here.
Expect BDX to range from $204.87 to $378.16 through 2032. The $268.83 average target implies a +83% move from current prices. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The BDX price prediction for 2033 points to an average of $301.97 (low $227.75, high $430.21) — a potential gain of +105% on today's $147.24. Momentum favours further upside here.
In 2034, BDX is projected to trade between $242.86 and $468.79, averaging $325.20 — a potential gain of +121% from today's $147.24. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Becton, Dickinson and Company's 2035 outlook centres on $331.67, within a $245.38 to $483.39 range. That is up +2% on the projected 2034 average. That marks a +125% change versus current levels. Momentum favours further upside here.
By 2040, BDX could reach as high as $752.87, with a base case around $493.07 and support toward $349.82 — roughly +235% from $147.24. Buyers look set to stay in control over this stretch.
Expect BDX to range from $591.50 to $1,462.84 through 2050. The $894.01 average target implies a +507% move from current prices. That is up +81% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BDX today (≈ 6.791633 BDX) could be worth
$6,071.77
+$5,071.77 (+507%) by 2050 · US Dollar
Based on the average projected BDX price of $894.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDXwould be worth at today's price.
$1,000 invested in BDX on May 27, 2025 (≈ 7.288981 BDX) would be worth
$1,073.23
+$73.23 (+7.3%) today · 1.07× · US Dollar
Based on a BDX entry price of $137.19 vs. today's $147.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $146.95 | $1,001.97 | +0.2% |
| 1 month ago | $150.22 | $980.16 | -2.0% |
| 3 months ago | $176.66 | $833.47 | -16.7% |
| 6 months ago | $152.53 | $965.31 | -3.5% |
| 1 year ago | $137.19 | $1,073.23 | +7.3% |
| All time (5.0y) ago | $182.9 | $805.01 | -19.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDX forecast.
Our base-case forecast reaches $290.00 around 2033.
Implied market cap at $290.00: $79.91B
Longer-term forecasts show a gradual acceleration in the average price and sizable ROI as time progresses. For 2026 the min is $142.35, the avg is $147.63, and the max is $206.99 with a 0% ROI and neutral sentiment.
From 2027 onward, the path strengthens, with 2027 avg $173.59 and ROI 17.6, 2028 avg $188.15 and ROI 27.4, and 2029 avg $209.95 with ROI 42.2. The 2030 forecast shows an avg of $210.87 and ROI 42.8, remaining bullish. By 2040, the forecast targets an avg of $519.23 with ROI 251.7 and a bullish sentiment, and by 2050 an avg of $941.25 with ROI 537.6 and bullish sentiment.
These figures illustrate a strong, long-run upside, though they come with uncertainty and are not guarantees. Risk factors are not detailed in the provided projections.
Tap a question to reveal the answer.
The 2030 forecast lists an avg of $210.87, with a min of $164.43 and a max of $288.09, and a ROI of 42.8% with bullish sentiment.
The projections show a bullish trajectory in later years, with 2027 avg $173.59 (ROI 17.6%), 2028 avg $188.15 (ROI 27.4%), 2029 avg $209.95 (ROI 42.2%), 2030 avg $210.87 (ROI 42.8%), 2040 avg $519.23 (ROI 251.7%), and 2050 avg $941.25 (ROI 537.6%), though these are estimates and not guarantees.
The forecast max for 2050 is $1,540.27, indicating a potential to exceed $1,000 in the long run, but these figures are not guaranteed and depend on future conditions.
The current price is $147.63. Near-term indicators show neutral momentum with RSI at 50, 50-day SMA $152.49, and 200-day SMA $154.60. The stock trades within a 30-day range of $132.81 to $164.10, with support at $142.35 and resistance at $158.64.
The long-term outlook points to significant upside by 2040 and 2050 based on the provided forecast (e.g., 2040 avg $519.23, 2050 avg $941.25), but the results are not guaranteed and come with inherent uncertainty. The forecast includes bullish sentiment for the later years and substantial potential returns, yet the exact drivers and risks are not detailed in the data.
Becton, Dickinson and Company Community Discussion
0Share your Becton, Dickinson and Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.